Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

39.67 -7.75 (-16.35%)
Streaming Delayed Price Updated: 11:08 AM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Why Eli Lilly Stock Just Popped ↗
Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly). 
Via The Motley Fool
News headline image
Why Novo Nordisk Stock Just Crashed ↗
GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for. 
Via The Motley Fool
News headline image
High Volatility and Earnings Crossroads: A Deep Dive into Hims & Hers Health (HIMS) in 2026
As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the... 
Via Finterra
Topics Artificial Intelligence Intellectual Property Lawsuit
Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report ↗
Via Stocktwits
News headline image
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head
Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing... 
Via MarketMinute
News headline image
Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial
COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated... 
Via MarketMinute
Topics Earnings
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock ↗
Novo Nordisk investors get a second bite at the Ozempic apple. 
Via The Motley Fool
News headline image
3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗
Viking stock has plenty of room to run. 
Via The Motley Fool
News headline image
Why Is NVO Stock Falling Pre-Market Today? ↗
The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint. 
Via Stocktwits
Topics Government
News headline image
2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $200 ↗
These two healthcare stocks are likely headed higher from their current prices. 
Via The Motley Fool
News headline image
Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside ↗
Via MarketBeat
News headline image
Novo Nordisk Stock Investors Just Got Great News From Eli Lilly ↗
But it's good news for Eli Lilly, too. 
Via The Motley Fool
News headline image
Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash? ↗
New products are already generating growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗
These biotech companies have catalysts ahead. 
Via The Motley Fool
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention ↗
Novo Nordisk looks attractively priced even though 2026 is likely to be a tough year. 
Via The Motley Fool
News headline image
Hims & Hers HUGE Acquisition News! ↗
Hims & Hers is acquiring Eucalyptus and spreading its wings internationally. 
Via The Motley Fool
News headline image
Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush ↗
Ozempic's rival is generating blockbuster revenue and gaining market share. 
Via The Motley Fool
News headline image
The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth
In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion... 
Via MarketMinute
Topics Earnings Economy
News headline image
NVO Stock Generates Retail Buzz After European Commission Approves 7.2 MG Once-Weekly Dose Of Wegovy Injection ↗
The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants. 
Via Stocktwits
Topics Lawsuit
News headline image
2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗
Viking should have plenty of news to share with investors this year. 
Via The Motley Fool
News headline image
Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy? ↗
Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape. 
Via The Motley Fool
News headline image
Got $500? 2 Pharma Stocks to Buy and Hold Forever. ↗
Growth, value, or both? 
Via The Motley Fool
News headline image
Novo Nordisk To Meet Wegovy Pill Demand In US Before Expanding To Avoid Supply Shortage, Says CEO Doustdar ↗
Novo is looking to ensure the U.S. market is supplied before choosing another country to scale in, Doustdar said in an interview with CNBC. 
Via Stocktwits
Topics Lawsuit
News headline image
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 ↗
Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally. 
Via The Motley Fool
Topics Intellectual Property
News headline image
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? ↗
The company ended 2025 with $706 million in cash, which it said is enough to fund ongoing Phase 3 trials and maintenance data readouts. 
Via Stocktwits
News headline image
Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. ↗
Both companies are betting on interest in weight loss pills. 
Via The Motley Fool
News headline image
Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs ↗
Novo Nordisk (NYSE: NVO) CEO Mike Doustdar said the company aims to reach about 15 million new patients when Medicare begins covering obesity treatments later this year. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.